Tag Archives: money
#436005 NASA Hiring Engineers to Develop “Next ...
It’s been nearly six years since NASA unveiled Valkyrie, a state-of-the-art full-size humanoid robot. After the DARPA Robotics Challenge, NASA has continued to work with Valkyrie at Johnson Space Center, and has also provided Valkyrie robots to several different universities. Although it’s not a new platform anymore (six years is a long time in robotics), Valkyrie is still very capable, with plenty of potential for robotics research.
With that in mind, we were caught by surprise when over the last several months, Jacobs, a Dallas-based engineering company that appears to provide a wide variety of technical services to anyone who wants them, has posted several open jobs in need of roboticists in the Houston, Texas, area who are interested in working with NASA on “the next generation of humanoid robot.”
Here are the relevant bullet points from the one of the job descriptions (which you can view at this link):
Work directly with NASA Johnson Space Center in designing the next generation of humanoid robot.
Join the Valkyrie humanoid robot team in NASA’s Robotic Systems Technology Branch.
Build on the success of the existing Valkyrie and Robonaut 2 humanoid robots and advance NASA’s ability to project a remote human presence and dexterous manipulation capability into challenging, dangerous, and distant environments both in space and here on earth.
The question is, why is NASA developing its own humanoid robot (again) when it could instead save a whole bunch of time and money by using a platform that already exists, whether it’s Atlas, Digit, Valkyrie itself, or one of the small handful of other humanoids that are more or less available? The only answer that I can come up with is that no existing platforms meet NASA’s requirements, whatever those may be. And if that’s the case, what kind of requirements are we talking about? The obvious one would be the ability to work in the kinds of environments that NASA specializes in—space, the Moon, and Mars.
Image: NASA
Artist’s concept of NASA’s Valkyrie humanoid robot working on the surface of Mars.
NASA’s existing humanoid robots, including Robonaut 2 and Valkyrie, were designed to operate on Earth. Robonaut 2 ended up going to space anyway (it’s recently returned to Earth for repairs), but its hardware was certainly never intended to function outside of the International Space Station. Working in a vacuum involves designing for a much more rigorous set of environmental challenges, and things get even worse on the Moon or on Mars, where highly abrasive dust gets everywhere.
We know that it’s possible to design robots for long term operation in these kinds of environments because we’ve done it before. But if you’re not actually going to send your robot off-world, there’s very little reason to bother making sure that it can operate through (say) 300° Celsius temperature swings like you’d find on the Moon. In the past, NASA has quite sensibly focused on designing robots that can be used as platforms for the development of software and techniques that could one day be applied to off-world operations, without over-engineering those specific robots to operate in places that they would almost certainly never go. As NASA increasingly focuses on a return to the Moon, though, maybe it’s time to start thinking about a humanoid robot that could actually do useful stuff on the lunar surface.
Image: NASA
Artist’s concept of the Gateway moon-orbiting space station (seen on the right) with an Orion crew vehicle approaching.
The other possibility that I can think of, and perhaps the more likely one, is that this next humanoid robot will be a direct successor to Robonaut 2, intended for NASA’s Gateway space station orbiting the Moon. Some of the robotics folks at NASA that we’ve talked to recently have emphasized how important robotics will be for Gateway:
Trey Smith, NASA Ames: Everybody at NASA is really excited about work on the Gateway space station that would be in near lunar space. We don’t have definite plans for what would happen on the Gateway yet, but there’s a general recognition that intra-vehicular robots are important for space stations. And so, it would not be surprising to see a mobile manipulator like Robonaut, and a free flyer like Astrobee, on the Gateway.
If you have an un-crewed cargo vehicle that shows up stuffed to the rafters with cargo bags and it docks with the Gateway when there’s no crew there, it would be very useful to have intra-vehicular robots that can pull all those cargo bags out, unpack them, stow all the items, and then even allow the cargo vehicle to detach before the crew show up so that the crew don’t have to waste their time with that.
Julia Badger, NASA JSC: One of the systems on board Gateway is going to be intravehicular robots. They’re not going to necessarily look like Robonaut, but they’ll have some of the same functionality as Robonaut—being mobile, being able to carry payloads from one part of the module to another, doing some dexterous manipulation tasks, inspecting behind panels, those sorts of things.
Image: NASA
Artist’s concept of NASA’s Valkyrie humanoid robot working inside a spacecraft.
Since Gateway won’t be crewed by humans all of the time, it’ll be important to have a permanent robotic presence to keep things running while nobody is home while saving on resources by virtue of the fact that robots aren’t always eating food, drinking water, consuming oxygen, demanding that the temperature stays just so, and producing a variety of disgusting kinds of waste. Obviously, the robot won’t be as capable as humans, but if they can manage to do even basic continuing maintenance tasks (most likely through at least partial teleoperation), that would be very useful.
Photo: Evan Ackerman/IEEE Spectrum
NASA’s Robonaut team plans to perform a variety of mobility and motion-planning experiments using the robot’s new legs, which can grab handrails on the International Space Station.
As for whether robots designed for Gateway would really fall into the “humanoid” category, it’s worth considering that Gateway is designed for humans, implying that an effective robotic system on Gateway would need to be able to interact with the station in similar ways to how a human astronaut would. So, you’d expect to see arms with end-effectors that can grip things as well as push buttons, and some kind of mobility system—the legged version of Robonaut 2 seems like a likely template, but redesigned from the ground up to work in space, incorporating all the advances in robotics hardware and computing that have taken place over the last decade.
We’ve been pestering NASA about this for a little bit now, and they’re not ready to comment on this project, or even to confirm it. And again, everything in this article (besides the job post, which you should totally check out and consider applying for) is just speculation on our part, and we could be wrong about absolutely all of it. As soon as we hear more, we’ll definitely let you know. Continue reading
Posted in Human Robots
#435575 How an AI Startup Designed a Drug ...
Discovering a new drug can take decades, billions of dollars, and untold man hours from some of the smartest people on the planet. Now a startup says it’s taken a significant step towards speeding the process up using AI.
The typical drug discovery process involves carrying out physical tests on enormous libraries of molecules, and even with the help of robotics it’s an arduous process. The idea of sidestepping this by using computers to virtually screen for promising candidates has been around for decades. But progress has been underwhelming, and it’s still not a major part of commercial pipelines.
Recent advances in deep learning, however, have reignited hopes for the field, and major pharma companies have started tying up with AI-powered drug discovery startups. And now Insilico Medicine has used AI to design a molecule that effectively targets a protein involved in fibrosis—the formation of excess fibrous tissue—in mice in just 46 days.
The platform the company has developed combines two of the hottest sub-fields of AI: the generative adversarial networks, or GANs, which power deepfakes, and reinforcement learning, which is at the heart of the most impressive game-playing AI advances of recent years.
In a paper in Nature Biotechnology, the company’s researchers describe how they trained their model on all the molecules already known to target this protein as well as many other active molecules from various datasets. The model was then used to generate 30,000 candidate molecules.
Unlike most previous efforts, they went a step further and selected the most promising molecules for testing in the lab. The 30,000 candidates were whittled down to just 6 using more conventional drug discovery approaches and were then synthesized in the lab. They were put through increasingly stringent tests, but the leading candidate was found to be effective at targeting the desired protein and behaved as one would hope a drug would.
The authors are clear that the results are just a proof-of-concept, which company CEO Alex Zhavoronkov told Wired stemmed from a challenge set by a pharma partner to design a drug as quickly as possible. But they say they were able to carry out the process faster than traditional methods for a fraction of the cost.
There are some caveats. For a start, the protein being targeted is already very well known and multiple effective drugs exist for it. That gave the company a wealth of data to train their model on, something that isn’t the case for many of the diseases where we urgently need new drugs.
The company’s platform also only targets the very initial stages of the drug discovery process. The authors concede in their paper that the molecules would still take considerable optimization in the lab before they’d be true contenders for clinical trials.
“And that is where you will start to begin to commence to spend the vast piles of money that you will eventually go through in trying to get a drug to market,” writes Derek Lowe in his blog In The Pipeline. The part of the discovery process that the platform tackles represents a tiny fraction of the total cost of drug development, he says.
Nonetheless, the research is a definite advance for virtual screening technology and an important marker of the potential of AI for designing new medicines. Zhavoronkov also told Wired that this research was done more than a year ago, and they’ve since adapted the platform to go after harder drug targets with less data.
And with big pharma companies desperate to slash their ballooning development costs and find treatments for a host of intractable diseases, they can use all the help they can get.
Image Credit: freestocks.org / Unsplash Continue reading
Posted in Human Robots